PP_1170x120_10-25-21

Pfizer

Pfizer-BioNTech COVID-19 vaccine offers strong immune response for kids

Pfizer-BioNTech COVID-19 vaccine offers strong immune response for kids

NEW YORK — Pfizer Inc. and BioNTech SE announced Monday topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to

Pfizer joins the Open Targets consortium

Pfizer joins the Open Targets consortium

HINXTON, UK — Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success

Ten top BioPharma companies announce formation of Accumulus Synergy to develop global data sharing platform

Ten top BioPharma companies announce formation of Accumulus Synergy to develop global data sharing platform

BURLINGAME, Calif. — Ten of the world’s leading biopharmaceutical companies announced the formation of a new non-profit corporation, Accumulus Synergy, which is intended to support interactions between industry and health authorities worldwide to enable real-time collaboration and data exchange, as well as data submission. Accumulus Synergy was formed on July 13, 2020, to develop a

Pfizer and BioNTech SE announce additional data on neutralizing antibody and T cell responses

Pfizer and BioNTech SE announce additional data on neutralizing antibody and T cell responses

NEW YORK— Pfizer and BioNTech SE announced additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The study results demonstrate that BNT162b2 elicits a combined adaptive humoral and cellular immune response against SARS-CoV-2 and provide insights into the composite nature of BNT162b2-induced T cell immunity.

Panel endorses widespread use of Pfizer COVID-19 vaccine in the U.S.

Panel endorses widespread use of Pfizer COVID-19 vaccine in the U.S.

WASHINGTON— A committee of top U.S. vaccine scientists recommended Thursday that the Food and Drug Administration authorize the first COVID-19 vaccine for Americans. This endorsement paves the way for a final decision by the FDA and mass vaccinations to begin within days in thousands of front-line heath care workers and nursing homes residents. After an

Today’s FDA panel meeting could lead to Pfizer getting vaccine emergency use okay

Today’s FDA panel meeting could lead to Pfizer getting vaccine emergency use okay

WASHINGTON — Commissioner Stephen Hahn said ahead of  today’s meeting of the Food and Drug Administration’s vaccine advisory panel is “an important day for all of America.” Pfizer’s COVID-19 vaccine faces one last hurdle as it races to become the first shot greenlighted in the U.S. — a panel of experts who will carefully scrutinize

U.K. authorizes Pfizer, BioNTech’s COVID-19 vaccine for emergency use

U.K. authorizes Pfizer, BioNTech’s COVID-19 vaccine for emergency use

LONDON — According to various published reports, the U.K. has became the first Western nation to grant emergency-use authorization for a COVID-19 vaccine, clearing a shot developed by Pfizer and BioNTech to be distributed in limited numbers wnext week. The two-shot vaccine is also being reviewed by the Food and Drug Administration in the U.S., where a

Pfizer seeking emergency use of its COVID-19 vaccine

Pfizer seeking emergency use of its COVID-19 vaccine

NEW YORK  — Pfizer and BioNTech SE announced they will submit a request Friday to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of

Mylan and Pfizer receive clearance from FTC for proposed combination of Mylan and Upjohn

Mylan and Pfizer receive clearance from FTC for proposed combination of Mylan and Upjohn

Hertfordshire, England – Mylan and Pfizer  announced that the U.S. Federal Trade Commission accepted a proposed consent order, which concludes the FTC’s review of the proposed combination of Mylan and Pfizer’s Upjohn Business. The parties have now obtained all required antitrust clearances for the proposed transaction. The combination will be effected through a Reverse Morris

1 2 3 4
Adheris Health